NASDAQ$YMAB
Y-mAbs Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Y-mAbs reported a 13% increase in Q4 2024 revenue, driven by growth in international sales and licensing revenue.
Y-mAbs' Q4 2024 revenue increased 13% year-over-year to $26.5 million, supported by international DANYELZA sales and a $2 million licensing payment. However, net loss widened to $6.8 million due to increased operating expenses and reduced gross profit margin. The company continues to expand its radiopharmaceutical business while strengthening the DANYELZA franchise.
- Q4 2024 revenue increased 13% year-over-year to $26.5 million.
- Net loss widened to $6.8 million, compared to a $1.0 million loss in Q4 2023.
- International DANYELZA sales surged 78% year-over-year to $7.7 million.
- Signed exclusive license agreement with Nobelpharma for DANYELZA in Japan.
Headline financials
Revenue & EPS history
Y-mAbs · Revenue · Quarterly
$26.5M
Forward guidance
Y-mAbs expects full-year 2025 revenue to range between $75 million and $90 million, with increased investments in radiopharmaceutical development and commercial expansion.
Tailwinds
- Projected 2025 revenue between $75M and $90M.
- Continued global expansion of DANYELZA with new licensing deals.
- Increased focus on radiopharmaceutical pipeline with ongoing clinical trials.
- Stable U.S. DANYELZA revenue despite market competition.
- Cost management efforts expected to extend cash runway into 2027.
Headwinds
- Declining U.S. DANYELZA revenue due to pricing and competition.
- Increased operating costs from new business realignment strategy.
- Potential pricing pressures in international markets.
- Higher R&D spending required for radiopharmaceutical programs.
- Uncertain regulatory timelines for new pipeline products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q4 2024
+2.2%
Avg return
Earnings day
-4.2%
Avg return
5 days after
-5.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+54.6%
Q4 2022
Best reaction
-21.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | +0.0% | +0.8% | |
| Q1 2025 | -11.4% | +0.2% | +14.0% | |
| Q4 2024 | -4.4% | -0.4% | -9.9% | |
| Q3 2024 | -4.4% | -15.2% | -32.3% | |
| Q2 2024 | -3.5% | +9.4% | +18.4% | |
| Q1 2024 | -21.1% | -25.4% | -28.7% | |
| Q4 2023 | +14.5% | +2.0% | -0.2% | |
| Q3 2023 | +6.1% | — | — | |
| Q2 2023 | -5.0% | — | — | |
| Q1 2023 | +33.6% | — | — | |
| Q4 2022 | +54.6% | — | — | |
| Q3 2022 | +15.4% | — | — | |
| Q2 2022 | -5.6% | — | — | |
| Q1 2022 | +13.2% | — | — | |
| Q4 2021 | +12.9% | — | — | |
| Q3 2021 | -19.7% | — | — | |
| Q2 2021 | -17.8% | — | — | |
| Q1 2021 | +20.8% | — | — | |
| Q4 2020 | -3.6% | — | — | |
| Q3 2020 | -3.0% | — | — | |
| Q2 2020 | -1.6% | — | — | |
| Q1 2020 | +14.4% | — | — | |
| Q4 2019 | -8.7% | — | — | |
| Q3 2019 | -1.6% | — | — | |
| Q2 2019 | +2.4% | — | — | |
| Q1 2019 | -9.9% | — | — | |
| Q4 2018 | -4.4% | — | — | |
| Q3 2018 | -1.1% | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro